

**EXHIBIT B**  
**EXCERPTS FROM THE DEPOSITION OF**  
**RAHUL GUPTA, M.D.**  
**04/15/2021**

IN THE UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA

\* \* \* \* \*

THE CITY OF HUNTINGTON,

Plaintiff,

vs.

CIVIL ACTION  
NO. 3:17-01362

AMERISOURCEBERGEN DRUG  
CORPORATION, et al.,  
Defendants.

-----  
CABELL COUNTY COMMISSION,  
Plaintiff,

vs.

CIVIL ACTION  
NO. 3:17-01665

AMERISOURCEBERGEN DRUG  
CORPORATION, et al.,  
Defendants.

\* \* \* \* \*

Videotaped and videoconference deposition  
of RAHUL GUPTA, M.D. taken by the Defendants under  
the Federal Rules of Civil Procedure in the above-  
entitled action, pursuant to notice, before Teresa  
S. Evans, a Registered Merit Reporter, all parties  
located remotely, on the 15th day of April, 2021.

1 period of time, you were in private practice and  
2 you held yourself out as an internist. Correct?

3 A. Amongst other areas as well, correct.

4 Q. And my question to you then, with that  
5 background, is: Have you ever held yourself out as  
6 an epidemiologist and solely an epidemiologist?

7 A. I still do not understand the nature of the  
8 question of being a physician solely as an  
9 epidemiologist. I can help to answer the question  
10 this way: That as the local health officer and  
11 physician director, which is the official position  
12 at Kanawha-Charleston Health Department, my role  
13 from March of 2009 to December of 2014 - which was  
14 almost six years - involved leading a team of  
15 epidemiologists in a variety of work that included  
16 conducting epidemiological surveys, studies,  
17 analysis and policy making as a result of that work  
18 for the largest county in the state of West  
19 Virginia, which is Kanawha County.

20 Following that, because partly of that  
21 work, the Governor of the state of West Virginia  
22 asked me to serve as the State Health Officer,  
23 which also requires to have - similar to  
24 Kanawha-Charleston Health Department - a

1 MS. MAINIGI: Okay, that's fine.

2 Q. Go ahead, Doctor Gupta.

3 A. So basically my work from 2015 and '16 and  
4 '17, it was the totality of the work that was  
5 recognized for this award. That really required a  
6 asserted effort from day one, so going back, very  
7 beginning, one of the first -- when I came into the  
8 office in January of 2015, it became my priority  
9 number one, priority number two and priority number  
10 three, to start addressing or help address the  
11 problem of the overdose deaths that we were facing,  
12 as well as the nonfatal overdoses and the carnage  
13 and the killing that was happening in West Virginia  
14 around the clock of people because of the opioid  
15 crisis.

16 So the first thing we did was: We  
17 created the first -- funded the first Harm  
18 Reduction Program by providing seed funding to  
19 Cabell-Huntington Health Department in Cabell  
20 County, so we initiated that program.

21 I helped not only fund, but helped  
22 begin that program with Doctor Kilkenny, as I  
23 mentioned, worked very closely with Doctor Kilkenny  
24 in Cabell-Huntington Health Department.

1                   We then continued to utilize the model  
2     of Cabell-Huntington Health Department's Harm  
3     Reduction Program to expand to other areas of the  
4     state. In early 2017, I continued to see 15 to 20  
5     percent rise in overdose deaths year after year  
6     after year, so along with working to write the 1115  
7     Medicaid waiver, expand -- remove the barriers to  
8     treatment, work legislation, create the Office of  
9     Drug Control Policy at the State level --

10                  One of the important things we did is:  
11     We conducted a social autopsy. The social autopsy  
12     that was conducted, we looked at all of the deaths  
13     from overdose that happened in 2016. We -- we did  
14     a CSI type of investigation to look at people's  
15     deaths in the year before their deaths.

16                  We had very significant findings that  
17     included that 90 percent of decedents have an  
18     interaction with the -- you know, the PDMP or the  
19     prescription drug monitoring -- Controlled  
20     Substances Monitoring Program in West Virginia, as  
21     we call it, and we found that a significant  
22     percentage of women -- so half of the women that  
23     died had filled a prescription within 30 days of  
24     their death.

1           We also found that if people went to  
2 multiple pharmacies, that chances was as high as 70  
3 percent of dying because of overdose. We -- so we  
4 had very significant findings like these, because  
5 of which then we -- I put together a team to create  
6 an opioid response plan of national and state  
7 experts, including John Hopkins University,  
8 Marshall University and West Virginia University.

9           They came out with a plan, 12-point  
10 plan. We -- I submitted that plan to the Governor.  
11 As a result of this, basically -- and I don't want  
12 to like take too much of this time. But what  
13 happened was: Before I came, the rate of  
14 prescription drugs and after I left, in the  
15 country, it was down by 30 percent; in West  
16 Virginia, because of these efforts, it was down by  
17 53 percent.

18           In 2017 to 2018, because of the work  
19 of 2017, the paper was recognized nationally, the  
20 outcomes that would happen. That was the only  
21 year, from 2017 to 2018, that the nation had any  
22 drops in overdose deaths, and nationally, there was  
23 a drop of about 4 percent average. But in West  
24 Virginia, because of this work, we had 11 percent

1 BY MS. MAINIGI:

2 Q. Doctor Gupta, I'm going to show you  
3 Statement No. 3, Bullet No. 3 of Exhibit 58.

4 MS. MAINIGI: Steve, could we scroll  
5 down to it, please?

6 MR. RUBY: Yep. There's a little lag  
7 here. Sorry.

8 MS. MAINIGI: Sorry.

9 Q. Okay. Doctor Gupta, why don't you take a  
10 moment and read that? Let me know when you're  
11 ready.

12 A. Okay.

13 Q. Okay. Statement 3 reads, "There is a  
14 direct correlation between diverted prescription  
15 pills and the transition to using street drugs such  
16 as heroin, fentanyl, methamphetamine, etc." Do you  
17 agree with this statement, Doctor Gupta?

18 A. Yes.

19 Q. And what is your basis for this statement?

20 A. Well, it's both the literature that exists  
21 to support that as well as my experience and the  
22 opinions that have resulted from my experience.

23 Q. Okay. Can you give me specific literature  
24 references that would support that statement,

1 Statement 3?

2 A. Sure. You know, as -- I think back as  
3 2014, Theo Cicero actually published a 50-year  
4 analyses in general psychiatry that showed that,  
5 you know, as much as 75 to 80 percent of the  
6 transition that was happening in people who were  
7 using heroin was actually -- they were the people  
8 that were in fact looking at -- nowadays, were  
9 transitioning from prescription drugs, as opposed  
10 to the '60s where 80 percent of people were going  
11 in the opposite direction.

12 So there's been a lot more literature  
13 since that that shows about 80 percent of the  
14 people that use heroin today have had their start  
15 from prescription opioids to begin with.

16 Now, having said that, we saw very  
17 similar facts in West Virginia. We started to see  
18 people that were often - because of a large volume  
19 and diversion that resulted often in addiction were  
20 utilizing prescription drugs, and as there was more  
21 policy and actions that were being taken to address  
22 that - part of that was reduction in supply - these  
23 people really often, as an example, when there was  
24 action on shutting down a pill mill, there were



1 often people that would then not have a supply.

2 As a result of that, they would either  
3 have two or three options. One option was to go to  
4 the emergency room. We saw flooding of the  
5 emergency room.

6 Second was to go to street drugs which  
7 were much more readily available, cheap in terms of  
8 heroin, or just die, overdose and die.

9 And we were seeing all of this. So  
10 our findings matched what was being published. In  
11 fact, there's been some work done by Sarah Mars in  
12 Philly population that also showed very similar  
13 numbers, and we were matching that up.

14 So as that began to happen, more and  
15 more people transitioned to heroin, there began an  
16 infiltration of cutting heroin with fentanyl by  
17 drug dealers primarily to save costs, to make more  
18 money.

19 And as that was happening, fentanyl,  
20 of course, is a substance that's about 80 times  
21 more potent than morphine, so because it was  
22 uncontrolled, we were seeing batches of deaths  
23 happening together because of bad batch of  
24 fentanyl-cut heroin.

1 Across West Virginia, that was the  
2 case. When we had in 2016, fall of 2016 or so, an  
3 outbreak in Huntington, West Virginia that was  
4 first but not the only of its kind across the  
5 country, where in a matter of hours, dozens of  
6 people were overdosed and had to be taken to the  
7 hospital.

8 This was an example of where disease  
9 from overdose was starting to simulate an  
10 infectious disease, meaning you have a patient zero  
11 and -- or -- which would actually be a drug dealer  
12 that would have a bad batch, and that many people  
13 would get impacted.

14 Same thing happened in Beckley during  
15 my tenure, and other places as well.

16 So that -- that first phase was  
17 prescription drugs. The second phase, because of  
18 increased volume -- the volume, diversion and  
19 addiction was actually getting it on.

20 And the action that followed was to  
21 transition to heroin. That was wave two, as CDC  
22 describes it.

23 The third wave was actually mixing of  
24 heroin with synthetic opioids like fentanyl, and I

1       were prescribed?

2             A.    Yes.

3             Q.    So that's a matter of fact, not opinion.  
4       Right?

5             A.    That's both a fact and an opinion.

6             Q.    Well, it can be empirically proven,  
7       correct, whether it's true or not true?

8             A.    It can be proven, and it also goes along  
9       with my experience as a physician and having to  
10      visit the neonatal ICUs across the state of West  
11      Virginia and neonatal ICUs across the country that  
12      I see that.

13            Q.    And other than what you saw anecdotally  
14      across the country and across West Virginia, was  
15      there some sort of systemic research or information  
16      compilation that was done by your department on  
17      this issue?

18            A.    Absolutely.

19            Q.    What was that?

20            A.    We, first of all, created a clinical  
21      definition for NAS that we had all the birthing  
22      facilities in the state of West Virginia, including  
23      Cabell County and City of Huntington's hospitals  
24      agree to.

1                   And all of the doctors - meaning the  
2     birthing physicians in Cabell County and all across  
3     West -- across West Virginia, agreed to a common  
4     definition. Once we did that, we then started to  
5     capture that definition and those diagnoses in a  
6     program called Birth Score out of West Virginia  
7     University.

8                   We worked very closely with experts in  
9     Marshall, at Marshall University, to measure the  
10    amount of NAS that was happening. And I'm using  
11    NAS intermittently with NOWS, which is neonatal  
12    opioid withdrawal syndrome, and we then  
13    characterized the rate of NAS per county, and we  
14    found that the average rate of NAS in the state was  
15    5 percent. That's 1 in 20 babies, which is the  
16    highest by far of any state in the nation.

17                  But we also found that some of the  
18    counties had much higher rate, to the tune of 10  
19    and over 10 percent. Again, that's a published  
20    report, available in the public domain. And I -- I  
21    don't have a -- you know, a lot of recollection  
22    about every aspect of it.

23                  Q. Do you remember who within your  
24    organization primarily did the research for that

1 report?

2 A. It would have been the -- under my  
3 supervision, the Department of Family and  
4 Children's Services.

5 Q. Statement 21. Let's turn to that for a  
6 moment. "Children diagnosed with at birth have  
7 noticeable difficulties learning and paying  
8 attention." Do you agree with that statement?

9 A. Once again, diagnosed with NAS is what's  
10 missing here, but if we could put "with" blank,  
11 because that's just -- it's an error in the  
12 statement.

13 Q. Okay.

14 A. So -- yeah.

15 Q. So with that "NAS" added, do you agree with  
16 that statement?

17 A. Yes.

18 Q. Now, you don't have any training in  
19 neonatology or pediatrics, correct?

20 A. Actually, I have had rotations during my  
21 training in pediatrics and neonatology.

22 Q. When you were a resident; is that correct?

23 A. When I was in medical school, and I don't  
24 remember if it was residency too. But I've also

1 done emergency room coverage that included -- as  
2 well as my primary care practice, that included  
3 children.

4 Q. Okay. And that includes neonatology as  
5 well?

6 A. I have not taken care of NICU babies, so  
7 no.

8 Q. Have you done any research on the incidence  
9 of attention or learning deficits in children  
10 diagnosed with NAS?

11 A. Not personally, I have not.

12 Q. Do you know what percentage of children  
13 diagnosed with NAS exhibit noticeable difficulties  
14 learning and paying attention?

15 A. We are just at the precipice and that data  
16 is evolving, so I can't tell you for certain what  
17 that percent is.

18 (Background noise.)

19 MS. MAINIGI: If someone is off mute,  
20 could you please go on mute? I hear some  
21 background or interference. Is there a --

22 MS. KEARSE: Someone needs to be put  
23 on mute.

24 (A discussion was had off the record

1                   after which the proceedings continued  
2                   as follows:)

3       BY MS. MAINIGI:

4           Q.    Doctor Gupta, do you have any studies or  
5       reports that would support the statement in 21 that  
6       you --

7           A.    Yes.

8           Q.    -- can give me?

9           A.    Yes.

10          Q.    What are they?

11          A.    There's a number of reports, including --  
12       if you go to the CDC website, and that clearly  
13       talks about some of the challenges in learning as  
14       well as memory development, cognitive development  
15       as a consequence of NAS.

16          Q.    Now, can you tell me what percentage of NAS  
17       diagnoses result from prescription opioid use  
18       versus illicit opioid use?

19          A.    Once again, very similar to people who die  
20       and you cannot tell in them because the metabolites  
21       are the same. To the developing baby, it doesn't  
22       really matter whether it's prescription or  
23       otherwise, so --

24                   What I can tell you is: We did

1 studies in West Virginia at Bureau of Public Health  
2 and we found that one out of five babies' cord  
3 blood had a substance positive. That was with --  
4 that was inclusive of prescription as well as  
5 illicit.

6 We also found that almost 15 percent  
7 of intrauterine exposure was positive for  
8 substances. And I believe that was prescriptions.

9 But once again, I don't have access to  
10 that data right now, so I cannot be 100 percent  
11 certain at this point.

12 Q. The one-out-of-five statistic, was that  
13 something that was published by --

14 A. Yes.

15 Q. -- by who?

16 A. We have published that. So the first study  
17 was published by -- by one of the neonatologists -  
18 we funded the study at CAMC - Doctor Stefan  
19 Maxwell.

20 Q. 22, "As children with NAS enter the  
21 classroom, there will be noticeable, interruptive  
22 and impulsive behavioral issues." Do you agree  
23 with that statement?

24 A. Yes.



1           Q. Are you making that statement as a mental  
2 health professional?

3           A. I'm making that statement as a Commissioner  
4 who has interacted with hundreds of teachers,  
5 school board members and parents and has learned a  
6 lot through interacting with actual West Virginians  
7 on the ground.

8                       It is my opinion with a reasonable  
9 degree of certainty that children, as they're  
10 growing up who are diagnosed initially with  
11 neonatal abstinence syndrome have a significant  
12 difficulty oftentimes with impulse control, with  
13 focus in classroom issues and may sometimes get  
14 misdiagnosed as ADD.

15           Q. Do you -- besides your own experience  
16 talking to teachers and so forth, do you have any  
17 studies that you can cite to?

18           A. Yes. So there's a lot of literature. I'm  
19 happy to share with you. Some of the folks that  
20 have worked on this is people like Stephen Patrick  
21 at Vanderbilt and others. That literature is there  
22 and is evolving and includes - which is not  
23 mentioned here - some of the birth defects as well  
24 of children with NAS.

1           Q.   Okay.  And let's go back to No. 8.  No. 8  
2   reads, "The opioid epidemic has lead to an increase  
3   in the number of children entering the foster care  
4   system, rapidly increasing child welfare costs to  
5   the state."  Do you agree with that statement?

6           A.   Yes.

7           Q.   Now, the foster care system in West  
8   Virginia was the responsibility of a different part  
9   of DHHR than your office; is that correct?

10          A.   That's correct.

11          Q.   You did not oversee the foster care system,  
12   did you?

13          A.   I did not.

14          Q.   Where did -- what's your basis for this  
15   statement then?

16          A.   In addition to being the Commissioner of  
17   the Bureau for Public Health, as I mentioned  
18   before, I'm also -- I was also the State Health  
19   Officer.  That being, it was my responsibility in  
20   that role to be overseeing the -- you know, number  
21   of other aspects of the public health system.

22                        So we interacted frequently with and  
23   worked closely with -- with the -- that particular  
24   department, as well as our parent department, which

1 is the Department of Health and Human Resources, as  
2 I -- and I reported to my boss, which is the  
3 Cabinet Secretary.

4 Now, clearly I was open to looking at  
5 the data for the foster care system, and saw and  
6 experienced in our budget presentations to the  
7 legislature each year that we worked together with  
8 the commissioners who create that, and we reported  
9 on this.

10 The Cabinet Secretary is on the record  
11 stating in his testimony - where I was present -  
12 that about 90 percent of the cost of foster system  
13 in West Virginia is associated in some form or  
14 other with the opioid crisis or the substance use  
15 disorder crisis.

16 So that's something that is on the  
17 record from my boss, and of course, it's my opinion  
18 based on that and some of the budgetary and other  
19 factors and working closely with the -- my  
20 co-agency, that this statement holds true with a  
21 substantial -- and again, a reasonable degree of  
22 certainty.

23 Q. So opioid prescription medications require  
24 a prescription; is that correct?